<DOC>
	<DOCNO>NCT00003562</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine docetaxel carboplatin treat patient stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Docetaxel Plus Carboplatin Treating Patients With Stage IIIB Stage IV Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine effectiveness low dose docetaxel carboplatin response rate , response duration , time progression patient stage IIIB IV non-small cell lung cancer . II . Determine side effect toxicity profile docetaxel give combination carboplatin patient . OUTLINE : This open label study . Patients receive docetaxel IV 1 hour follow carboplatin IV 30 minute week 4 week . Patients receive least 2 course ( 8 week ) treatment . Courses repeat absence unacceptable toxicity disease progression . PROJECTED ACCRUAL : There 20-38 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IIIB metastatic pleural effusion metastatic stage IV nonsmall cell lung cancer Large cell Adenocarcinoma Squamous cell Bronchioalveolar carcinoma Undifferentiated No small cell carcinoid histology At least 1 bidimensionally measurable evaluable indicator lesion Measurable evaluable indicator lesion ( ) must completely outside radiation portal must proof disease progression No current CNS metastasis study entry No meningeal carcinomatosis PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : Greater 12 week Hematopoietic : Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great upper limit normal ( ULN ) SGOT and/or SGPT great 2.5 time ULN alkaline phosphatase less ULN , OR alkaline phosphatase great 4 time ULN SGOT and/or SGPT less ULN Renal : Creatinine clearance least 50 mL/min Other : No concurrent illness would effect assessment study Not pregnant nursing Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior systemic chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Prior radiotherapy nonsmall cell lung cancer allow Radiotherapy new brain metastasis ( leptomeningeal disease ) allow study , chemotherapy stop 2 week follow radiotherapy Concurrent radiotherapy sit allow objective criterion disease progression Surgery : Not specify Other : No concurrent experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2001</verification_date>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
</DOC>